Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
November 04, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
- Robust In Vivo Data Presented at Scientific Meetings Support Advancement of Dyne’s Co-lead Candidates into the Clinic - - Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD...
Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day
October 13, 2021 07:45 ET
|
Dyne Therapeutics, Inc.
- Investigational New Drug (IND) Submissions Anticipated for DYNE-251 in DMD During the Fourth Quarter of 2021 and for DYNE-101 in DM1 During the First Quarter of 2022 - - Event also Features...
Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression
October 01, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
- Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model - - DYNE-251 Achieves...
Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021
September 28, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
- “The Muscle to Move to the Clinic” Event Will Highlight Preclinical Data Supporting Advancement of Dyne’s DM1 and DMD Programs Toward Clinical Trials and Anticipated Timelines, and Feature Leading...
Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
September 27, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress
September 20, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
- New In Vivo Data Also Show Sustained Knockdown of Toxic Human Nuclear DMPK RNA and Foci Reduction - - DM1 Program is One of Three IND Submissions Planned Between the Fourth Quarter of 2021 and the...
Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
August 05, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 -- New In Vivo Data from DM1 and DMD Programs to be Presented at Scientific...
Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
June 25, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
- FORCE™ platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line - WALTHAM, Mass., June 25, 2021 (GLOBE...
Dyne Therapeutics Announces Chief Scientific Officer Transition
June 02, 2021 16:05 ET
|
Dyne Therapeutics, Inc.
- Co-founder Romesh Subramanian, Ph.D., stepping down as chief scientific officer and will serve as an advisor after leading successful R&D and pipeline-building efforts - - Oxana Beskrovnaya,...
Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference
May 26, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with...